Terminated PHASE3 INTERVENTIONAL 2-arm NCT00562692

Role of Natriuretic Peptides in the Treatment of Acutely Decompensated Heart Failure Patient With Obstructive Airways Disease (BNP in OAD)

Sponsor: Janssen-Cilag Pty Ltd

Updated 6 times since 2017 Last updated: Jun 23, 2015 Started: Sep 30, 2007 Primary completion: Jul 31, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Recruitment very difficult. Study drug expired so we have stopped the study.

Other terminated trials from Janssen-Cilag Pty Ltd

More terminations from Janssen-Cilag Pty Ltd

Other Heart Failure trials with similar outcome

Browse all Heart Failure trials

This PHASE3 trial investigates Heart Failure and is currently terminated or withdrawn. Janssen-Cilag Pty Ltd leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen-Cilag Pty Ltd
The Alfred

Data source: The Alfred

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia